Novavax Developing Coronavirus Vaccine Candidate, Company Says

Jan. 21, 2020, 7:41 PM UTC

Novavax is working on a vaccine candidate in response to the coronavirus sweeping across China and now thought to have reached the U.S., the company said in an email. The vaccine developer shares rallied as much as 67%, the most intraday in more than 10 years, as fears of global contagion spread.

  • NVAX plans to use recombinant nanoparticle vaccine technology for a vaccine candidate, a third party spokeswoman said via email
    • NVAX’s Matrix-M platform will be used to bolster potential immune responses
  • Meanwhile, not everyone was optimistic, with a B Riley FBR analyst saying there’s “more questions than answers on ...





Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.